MedTrace Logo

A Dose-response Study With Strontium Malonate in Postmenopausal Women

NCT00409032 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2009-10-23

No results posted yet for this study

Summary

The primary objective of the study is to compare dose-response effect of three dose levels of strontium malonate to placebo on bone resorption quantified by S-CTX-1 following 12 weeks of treatment.

Conditions

Interventions

DRUG

Strontium malonate

Sponsors & Collaborators

  • Osteologix

    lead INDUSTRY

Principal Investigators

  • Richard Eastell, Professor, M.D. · University of Sheffield, Metabolic Bone Centre, Northern General Hospital, Sheffield S5 7AU, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-08-31
Completion
2007-09-30

Countries

  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00409032 on ClinicalTrials.gov